Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Gastric Cancer

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 37 articles: HTML format

Single Articles

December 2025
1. ZHAI C, Ying M, Wang X, Liu Z, et al
   Prior immunotherapy enhances survival outcomes of third-line apatinib treatment in advanced gastric cancer: A retrospective cohort study.
   Int J Cancer. 2025 Dec 29. doi: 10.1002/ijc.70322.
   PubMed     Abstract available
   
   
   
2. MA X, Ou K, Liu X, Cao B, et al
   Efficacy and safety of fruquintinib combined with albumin-bound paclitaxel as second-line therapy for advanced gastric cancer following failure of PD-1 inhibitor-containing treatment (TACTIC GC-01): A phase II single-arm study.
   Int J Cancer. 2025 Dec 25. doi: 10.1002/ijc.70299.
   PubMed     Abstract available
   
   
   
3. MATSUBARA Y, Masuishi T, Hosoda W, Hirano H, et al
   Ramucirumab-containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum-based chemotherapy: A multicenter observational retrospective study (WJOG13420G).
   Int J Cancer. 2025;157:2577-2588.
   PubMed     Abstract available
   
   
   
4. KRAEMER M, Wirsik NM, Alakus H, Schloesser HA, et al
   Adjuvant FLOT provides survival benefit for oesophagogastric junction and gastric adenocarcinoma patients with low tumour regression after neoadjuvant chemotherapy.
   Int J Cancer. 2025;157:2558-2568.
   PubMed     Abstract available
   
   
   
5. CASTILLO-ITURRA J, Llach J, Luzko I, Aguilera L, et al
   Performance of upper gastrointestinal endoscopy in CDH1 germline pathogenic variant carriers: A multicenter study.
   Int J Cancer. 2025;157:2550-2557.
   PubMed     Abstract available
   
   
   November 2025
6. DOEVE BH, Kuijper SC, Silversmit G, van Walle L, et al
   Treatment and survival of patients with esophageal and gastric cancer in the Netherlands and Belgium: A population-based comparison.
   Int J Cancer. 2025 Nov 19. doi: 10.1002/ijc.70225.
   PubMed     Abstract available
   
   
   
7. YUE P, Zhou Z, Li Z, Du C, et al
   Peritoneal lavage fluid minimal residual cancer cells detection for early prediction of peritoneal metastasis in gastric cancer: A multi-cohort validation study.
   Int J Cancer. 2025 Nov 14. doi: 10.1002/ijc.70233.
   PubMed     Abstract available
   
   
   August 2025
8. MA S, Zhang Y, Xie S, Li X, et al
   Balanced diet quality and risk of upper gastrointestinal cancers: Insights from a prospective cohort study in China.
   Int J Cancer. 2025;157:658-671.
   PubMed     Abstract available
   
   
   July 2025
9. LIU Y, Xue Q, Wang B, Ding X, et al
   Conversion therapy with sintilimab combined with chemotherapy and apatinib in stage IV gastric cancer.
   Int J Cancer. 2025 Jul 2. doi: 10.1002/ijc.35511.
   PubMed     Abstract available
   
   
   June 2025
10. GEERTS JFM, Vissers PAJ, Mostert B, Wijnhoven BPL, et al
    Hospital variation in treatment for synchronous metastatic esophageal and gastric cancer: A nationwide population-based study in the Netherlands.
    Int J Cancer. 2025 Jun 5. doi: 10.1002/ijc.35491.
    PubMed     Abstract available
    
    
    
11. CHAN WC, Millwood I, Kartsonaki C, Du H, et al
    Adiposity and risks of gastrointestinal cancers: A 10-year prospective study of 0.5 million Chinese adults.
    Int J Cancer. 2025;156:2094-2106.
    PubMed     Abstract available
    
    
    May 2025
12. PELC Z, Sedlak K, Mlak R, Endo Y, et al
    Impact of prognostic nutritional index on oncological outcomes and mortality among advanced gastric cancer patients: European GASTRODATA registry analysis.
    Int J Cancer. 2025 May 28. doi: 10.1002/ijc.35489.
    PubMed     Abstract available
    
    
    March 2025
13. JIANG XW, Zhang L, Liu ZC, Zhou T, et al
    Integrative metabolomics and microbiomics analysis reveals distinctive microbiota-metabolites interactions in gastric carcinogenesis.
    Int J Cancer. 2025 Mar 10. doi: 10.1002/ijc.35392.
    PubMed     Abstract available
    
    
    
14. ENGLISH KA, Goldsworthy M, Willis B, Kooblall KG, et al
    Calcium sensing receptor expression is downregulated in gastroenteropancreatic neuroendocrine tumours via epigenetic mechanisms.
    Int J Cancer. 2025;156:980-992.
    PubMed     Abstract available
    
    
    January 2025
15. SLOTMAN E, Pape M, van Laarhoven HWM, Pouw RE, et al
    Considerations to forgo systemic treatment in patients with advanced esophageal or gastric cancer: A real-world evidence study.
    Int J Cancer. 2025 Jan 9. doi: 10.1002/ijc.35314.
    PubMed     Abstract available
    
    
    December 2024
16. SEWASTJANOW-SILVA M, Kwiatkowski E, Yamashita K, Abdelhakeem A, et al
    Three biomarkers (HER2, PD-L1, and microsatellite status) in a large cohort of metastatic gastroesophageal adenocarcinomas: The MD Anderson Cancer Center experience.
    Int J Cancer. 2024;155:2277-2286.
    PubMed     Abstract available
    
    
    
17. INOUE-CHOI M, Freedman ND, Etemadi A, Hashemian M, et al
    One-carbon metabolism biomarkers and upper gastrointestinal cancer in the Golestan Cohort Study.
    Int J Cancer. 2024;155:1944-1957.
    PubMed     Abstract available
    
    
    October 2024
18. YAN X, Zeng H, Li H, Cao M, et al
    The current infection with Helicobacter pylori and association with upper gastrointestinal lesions and risk of upper gastrointestinal cancer: Insights from multicenter population-based cohort study.
    Int J Cancer. 2024;155:1203-1211.
    PubMed     Abstract available
    
    
    August 2024
19. LIU J, Gan T, Hu W, Li Y, et al
    Does ambient particulate matter 1 increase the risk of gastric cancer in the northwest of China?
    Int J Cancer. 2024 Aug 23. doi: 10.1002/ijc.35144.
    PubMed     Abstract available
    
    
    July 2024
20. WANG R, Chen XZ
    Comment on "Infectious pathogens and risk of esophageal, gastric and duodenal cancers and ulcers in China: A case-cohort study".
    Int J Cancer. 2024;155:184-185.
    PubMed    
    
    
    June 2024
21. MASETTI M, Al-Batran SE, Goetze TO, Thuss-Patience P, et al
    Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy.
    Int J Cancer. 2024;154:2142-2150.
    PubMed     Abstract available
    
    
    
22. NAGEL G, Chen J, Jaensch A, Skodda L, et al
    Long-term exposure to air pollution and incidence of gastric and the upper aerodigestive tract cancers in a pooled European cohort: The ELAPSE project.
    Int J Cancer. 2024;154:1900-1910.
    PubMed     Abstract available
    
    
    May 2024
23. GONZALEZ-PALACIOS S, Compan-Gabucio LM, Torres-Collado L, Oncina-Canovas A, et al
    The protective effect of dietary folate intake on gastric cancer is modified by alcohol consumption: A pooled analysis of the StoP Consortium.
    Int J Cancer. 2024 May 16. doi: 10.1002/ijc.35004.
    PubMed     Abstract available
    
    
    December 2023
24. SASAHARA M, Kanda M, Tanaka C, Shimizu D, et al
    Therapeutic antibody targeting natriuretic peptide receptor 1 inhibits gastric cancer growth via BCL-2-mediated intrinsic apoptosis.
    Int J Cancer. 2023 Dec 27. doi: 10.1002/ijc.34831.
    PubMed     Abstract available
    
    
    
25. ZHANG Q, Zhou Y, Song L, Fang W, et al
    China special issue on gastrointestinal tumors-Improved survival after multidisciplinary team decision for patients with advanced gastrointestinal cancer: A multicenter, noninterventional, controlled study.
    Int J Cancer. 2023;153:1885-1893.
    PubMed     Abstract available
    
    
    November 2023
26. GOETZE TO, Stein A, Lorenzen S, Habibzada T, et al
    Ramucirumab beyond progression plus TAS-102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab-based therapy.
    Int J Cancer. 2023;153:1726-1733.
    PubMed     Abstract available
    
    
    
27. RIJKEN A, Pape M, Simkens GA, de Hingh IHJT, et al
    Peritoneal metastases from gastric cancer in a nationwide cohort: Incidence, treatment and survival.
    Int J Cancer. 2023 Nov 2. doi: 10.1002/ijc.34780.
    PubMed     Abstract available
    
    
    October 2023
28. FAN XH, Zhang Y, Wang P, Song QQ, et al
    A noninvasive multianalytical approach establishment for risk assessment and gastric cancer screening.
    Int J Cancer. 2023 Oct 16. doi: 10.1002/ijc.34739.
    PubMed     Abstract available
    
    
    September 2023
29. LLACH J, Salces I, Guerra A, Penas B, et al
    Endoscopic surveillance for familial intestinal gastric cancer in low-incidence areas: An effective strategy.
    Int J Cancer. 2023 Sep 7. doi: 10.1002/ijc.34714.
    PubMed     Abstract available
    
    
    
30. PALOMAR-CROS A, Straif K, Romaguera D, Aragones N, et al
    Consumption of aspartame and other artificial sweeteners and risk of cancer in the Spanish multicase-control study (MCC-Spain).
    Int J Cancer. 2023;153:979-993.
    PubMed     Abstract available
    
    
    August 2023
31. CHENG L, Chang Y, Xia Z, Liu Y, et al
    Remote modulation of WWOX by an intronic variant associated with survival of Chinese gastric cancer patients.
    Int J Cancer. 2023 Aug 24. doi: 10.1002/ijc.34703.
    PubMed     Abstract available
    
    
    
32. CAO F, Sun H, Yang Z, Bai Y, et al
    Multiple approaches revealed MGc80-3 as a somatic hybrid with HeLa cells rather than a gastric cancer cell line.
    Int J Cancer. 2023 Aug 6. doi: 10.1002/ijc.34677.
    PubMed     Abstract available
    
    
    July 2023
33. GOETZE TO, Hofheinz RD, Gaiser T, Schmalenberg H, et al
    Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM.
    Int J Cancer. 2023;153:153-163.
    PubMed     Abstract available
    
    
    March 2023
34. GHASEMI-KEBRIA F, Semnani S, Fazel A, Etemadi A, et al
    Esophageal and gastric cancer incidence trends in Golestan, Iran: an age-period-cohort analysis 2004-2018.
    Int J Cancer. 2023 Mar 21. doi: 10.1002/ijc.34518.
    PubMed     Abstract available
    
    
    
35. MOHRING C, Manczak A, Timotheou A, Sadeghlar F, et al
    Perioperative Therapy with Flot4 Significantly Increases Survival in Patients with Gastroesophageal and Gastric Cancer in A Large Real-World Cohort.
    Int J Cancer. 2023 Mar 15. doi: 10.1002/ijc.34511.
    PubMed     Abstract available
    
    
    
36. KUIJPER SC, Pape M, Vissers PAJ, Jeene PM, et al
    Trends in best-case, typical and worst-case survival scenarios of patients with non-metastatic esophagogastric cancer between 2006 and 2020: a population-based study.
    Int J Cancer. 2023 Mar 1. doi: 10.1002/ijc.34488.
    PubMed     Abstract available
    
    
    February 2023
37. PAPE M, Kuijper SC, Vissers PAJ, Ruurda JP, et al
    Conditional relative survival in non-metastatic esophagogastric cancer between 2006 and 2020: a population-based study.
    Int J Cancer. 2023 Feb 25. doi: 10.1002/ijc.34480.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gastric Cancer is free of charge.